Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Alhosin, Mahmoud; Omran, Ziad; Zamzami, Mazin; Al-Malki, Abdulrahman; Choudhry, Hani; Mousli, Marc; Bronner, Christian
• Is Part Of: Journal of experimental & clinical cancer research. Volume 35:Issue 1(2016)
• Page Start: 1
• Page End: 11
• Publication Date: 2016-12
• Subjects: Epigenetic -- DNA methylation -- p16INK4A -- p53 -- p73 -- Tumor suppressor genes -- UHRF1; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s13046-016-0453-5
• Languages: English
• ISSNs: 1756-9966

Abstract

Abstract Epigenetic silencing of tumor suppressor genes (TSGs) through DNA methylation and histone changes is a main hallmark of cancer.U biquitin-like with PH D andR INGF inger domains1 (UHRF1) is a potent oncogene overexpressed in various solid and haematological tumors and its high expression levels are associated with decreased expression of several TSGs includingp16 INK4A, BRCA1, PPARG andKiSS1 . Using its several functional domains, UHRF1 creates a strong coordinated dialogue between DNA methylation and histone post-translation modification changes causing the epigenetic silencing of TSGs which allows cancer cells to escape apoptosis. To ensure the silencing of TSGs during cell division, UHRF1 recruits several enzymes including histone deacetylase 1 (HDAC1), DNA methyltransferase 1 (DNMT1) and histone lysine methyltransferases G9a and Suv39H1 to the right place at the right moment. Several in vitro and in vivo works have reported the direct implication of the epigenetic player UHRF1 in tumorigenesis through the repression of TSGs expression and suggested UHRF1 as a promising target for cancer treatment. This review describes the molecular mechanisms underlying UHRF1 regulation in cancer and discusses its importance as a therapeutic target to induce the reactivation of TSGs and subsequent apoptosis.